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Abstract
Background: Dentatorubropallidoluysian atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disease
that is associated with numerous movement disorders. Ocular problems also occur with DRPLA with reports of
corneal endothelial degeneration in some patients living with the disease. We report a new visual problem
associated with DRPLA, optic atrophy.
Case presentation: A 47 year-old man presented complaining of progressive visual loss associated with optic
atrophy on ophthalmological evaluation. He gradually developed a progressive ataxia with dystonia. Brain MRI
revealed a diffuse leukoencephalopathy. Genetic analysis revealed 62 CAG repeats in one allele of the DRPLA gene
and he was diagnosed with DRPLA.
Conclusion: Optic atrophy should be included in the clinical spectrum of DRPLA.
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Background
Dentatorubropallidoluysian Atrophy (DRPLA) is a rare
autosomal dominant neurodegenerative disease cha-
racterized by a variety of symptoms and signs including
progressive ataxia, choreoathetosis, dementia, myoclonus,
psychiatric problems, and seizures [1, 2]. DRPLA is most
common in Japan and very rare outside of Asia, however
there are multiple North American and European pedi-
grees [2–7]. A large African-American pedigree with
“Haw River Syndrome” (HRS) was eventually discovered
to have DRPLA [2, 3]. The pathogenesis of DRPLA
involves expanded CAG repeats in the DRPLA gene on
chromosome 12p13 leading to a polyglutamine expansion
in the Atrophin-1 protein and neuronal intranuclear
inclusions [8].
DRPLA is associated with visual disturbances in some
patients due to corneal endothelial degeneration [9, 10].
To our knowledge, there are no reports of optic atrophy
associated with DRPLA. We describe an African-American
man with DRPLA who presented with progressive visual
loss associated with optic atrophy, gradually progressive
ataxia, dystonia and severe leukoencephalopathy.
Case presentation
A 47 year-old African-American man presented to an
ophthalmologist for progressive worsening in his vision.
He had no prior history of reversible neurological defi-
cits that would be concerning for demyelinating disease
and no episodes of sudden visual loss. The temporal
field of vision in his left eye was impaired due to an
injury he sustained in a football game 25 years earlier,
however he noted progressive visual loss bilaterally over
the last several years. Examination of his visual acuity
with a Snellen chart at the time revealed 20/30 acuity in
the right eye and 20/70 acuity in the left eye. Four years
earlier, he had 20/30 acuity on the right and 20/50 on
the left. Ophthalmological evaluation revealed normal
corneas, normal intraocular pressures, optic atrophy
bilaterally (Fig. 1), and a swinging flashlight test revealed
a left afferent pupillary defect. Given the diagnostic pos-
sibilities of a chiasmatic tumor or multiple sclerosis, a
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brain MRI was ordered and showed diffuse white matter
disease involving the pons and the subcortical fronto-
parietal regions concerning for microischemic small
vessel disease. The optic nerves and optic chiasm were
also thought to be atrophic by the interpreting neu-
roradiologist. The patient had no history of exposure to
optic neurotoxins such as methanol, ethambutol, or
chloroquine. He was diagnosed with hypertension
around this time and treated with fosinopril and hydro-
chlorothiazide. There was no personal or family history
of a genetic disorder. The patient’s mother died of dia-
betes complications at an unknown age and his father
died at age 68 of “old age”. There was no known optic
atrophy or progressive significant visual loss and no
movement disorders in his parents. His brother was
known to have “fidgety” movements of his limbs con-
cerning for chorea, but he was never formally diag-
nosed with any disease. His two children were deceased
(one due to a gun-shot wound to the head) and neither
child ever displayed any visual problems or neurological
problems. He had nine grandchildren and five great
grandchildren, none of whom had visual problems or
neurological problems.
On initial neurological evaluation he was noted to
have dysmetria on both finger-to-nose and heel-to-shin
on the left and an unstable tandem gait. A work-up
revealed an unremarkable trans-thoracic echocardiogram,
elevated total cholesterol at 261, a negative ANA, ESR of
4, a non-reactive RPR, normal vitamin B-12 level, normal
blood glucose, normal CBC, negative HIV-1 testing, and a
normal serum lactate.
His vision and ataxia progressively worsened and a
brain MRI at age 53 revealed severe leukoencephalopa-
thy (Fig. 2). In addition, cerebellar atrophy with fourth
ventricle ex vacuo dilatation and brain stem volume loss
was evident (Fig. 2). Given the progressive nature of his
disorder we undertook a search for possible genetic
causes of ataxia. Following appropriate counseling, com-
mercially available genetic testing was performed for
autosomal dominant causes of ataxia including SCA1,
SCA2, SCA3, SCA6, SCA7, SCA8, SCA17, and DRPLA.
While negative for all other SCAs, the patient had 62
CAG repeats in one DRPLA allele and 12 CAG repeats in
the other allele. He was diagnosed with DRPLA and
counseled about the testing results. OPA1 (autosomal
dominant optic atrophy) genetic testing was not commer-
cially available and this genetic test was not performed.
At age 57, the patient remained fully oriented, retained
3/3 immediate and remote recall and displayed pseudo-
bulbar affect. He no longer drove due to incoordination
and visual problems, but managed his activities of daily
living. He had dysarthric, scanning speech, slowed verti-
cal and horizontal saccades, and dystonic posturing of
his right upper extremity and face at times. There was
no choreoathetosis or myoclonus evident. He had sig-
nificant dysmetria on finger-to-nose and heel-to-shin
bilaterally, dysdiadochokinesia and significant gait ataxia
requiring a cane for ambulation.
His uncorrected visual acuity had declined to being
able to only count fingers from one foot inward OS and
20/300 OD. Visual fields were severely constricted OS.
Slit lamp examination revealed corneas with 2-3+ guttata
and endothelial haze bilaterally most likely representing
endothelial degeneration due to DRPLA. Intraocular
pressures remained normal bilaterally and he had mild
bilateral cataracts. Fundoscopy again showed bilateral pale
optic discs consistent with optic atrophy, more pro-
nounced in the left eye.
Eleven years after initial presentation the patient was
admitted to a nursing home due to inability to care for
himself secondary to DRPLA. The patient eventually
died after 14 years of disease.
Conclusions
In this case, we described an African-American man who
presented with optic atrophy, ataxia and leukoencephalo-
pathy. Progressive decline in his vision, coordination and
gait as well as progression in his leukoencephalopathy was
evident upon serial examinations and repeat brain MRI
six years later. He was eventually diagnosed with DRPLA
following genetic testing. We could not identify other
causes of optic atrophy in this patient, and we feel it is
most likely related to DRPLA given his extensive white
matter disease. While hypertension may have contributed
Fig. 1 Optic atrophy on fundoscopic exam in DRPLA. Very pale optic discs are evident bilaterally. a OS, and (b) OD
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to the progression of his leukoencephalopathy, DRPLA
itself is associated with severe leukoencephalopathy
over time and was the likely major contributor in our
patient [3–5, 7, 11–13].
Unlike the African-American family identified as
having HRS that was later discovered to be DRPLA, our
patient did not have extensive basal ganglia calcifica-
tions, but did have extensive leukoencephalopathy as
seen in HRS [3, 4]. Another distinguishing clinical fea-
ture of our patient is the absence of significant dementia
at present. DRPLA, like SCA3 and Huntington’s disease,
can have a quite variable phenotype depending on the
number of CAG repeats, the race of the patient and
associated comorbidities [1–8, 14].
To our knowledge, DRPLA has not been implicated as a
cause of optic atrophy. Typical MRI findings in DRPLA
include cortical and cerebellar atrophy and degeneration
of the dentatorubral and pallidoluysian systems [11, 12].
Neuropathological findings in DRPLA vary and can
include basal ganglia calcifications and central demye-
lination as well as neuronal loss and astrogliosis in the
globus pallidus, dentate nucleus and subthalamic
nucleus [1–8, 13]. We cannot identify prior MRI or
neuropathological reports of optic atrophy even in older
DRPLA patients with significant visual loss and severe
leukoencephalopathy [7]. Other than the novel finding of
optic atrophy, our patient’s clinical and neuroimaging
features are typical of the DRPLA spectrum.
Corneal endothelial degeneration certainly could have
contributed to our patient’s progressive visual loss and it
is probably much more common in DRPLA than
realized. Despite the first description of DRPLA by
Smith et al. in 1958 [15], the first report of corneal
endothelial degeneration in DRPLA was not until 1999
[9]. The corneal endothelium is derived from neuroecto-
derm and there is expression of the DRPLA gene in
these cells leading to degeneration over time [9, 10].
Corneal endothelial degeneration was present in our pa-
tient as evidenced by the endothelial haze and 2–3+ gut-
tata noted on his last ophthalmological examination.
The lack of prior reports of optic atrophy associated
with DRPLA may be analogous to the long delay in the
discovery of corneal endothelial degeneration in these
patients. Alternatively, unknown racial, genetic or envir-
onmental influences in the setting of a predisposing con-
dition for white matter disease (DRPLA) could have led
to the optic atrophy.
The optic nerve and retina are CNS structures and the
astrocytes and oligodendrocytes of the optic nerve would
theoretically be predisposed to the same DRPLA disease
process as in the cerebral subcortical white matter.
Atrophin-1 may have a possible role in co-repressing
Fig. 2 MRI of the brain demonstrating characteristic findings in DRPLA. a Mid-sagittal T1-weighted image illustrating cerebellar atrophy and central
pontine hypointensity. b, c, d Axial FLAIR images demonstrating atrophy of the dentate with 4th ventricular ex vacuo dilatation (b), midline cerebellar
atrophy (c), and confluent hyperintense leukoencephalopathy (d). e Axial T1-weighted imaging demonstrating confluent white matter hypointensity in
approximately the same area as (d)
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orphan nuclear receptor TLX, involved in retinal progeni-
tor cell proliferation [16]. Other SCAs can be associated
with optic atrophy (especially in SCA1) and thinning of
the retinal nerve fiber layer by optical coherence tomog-
raphy (OCT) [17–19]. Interestingly, ocular manifestations
are not typically seen in SCA3 mouse models.
It appears that the diffuse leukoencephalopathy associ-
ated with DRPLA is more common in patients with a
greater number of CAG repeats and is more common in
older DRPLA sufferers [7, 8, 13]. White matter degener-
ation in DRPLA could be due to neurodegeneration
from expression of abnormal Atrophin-1 or due to influ-
ences on cerebral small vessels leading to diffuse ische-
mia [7, 8, 13]. Recent research indicates that abnormal
metabolism of polysaccharides in endothelial cells,
astrocytes and oligodendrocytes and/or microvasculature
dysfunction may contribute to white matter damage in
DRPLA [13]. Both of these processes are possible con-
tributors to the pathogenesis of optic atrophy we ob-
served in our patient.
Clinicians should be aware that DRPLA can be associ-
ated with optic atrophy.
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